Array Biopharma Inc
ARRY
ARRY was delisted on the 29th of July, 2019.
157 hedge funds and large institutions have $653M invested in Array Biopharma Inc in 2015 Q3 according to their latest regulatory filings, with 26 funds opening new positions, 57 increasing their positions, 44 reducing their positions, and 16 closing their positions.
63% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 16
30% more repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 44
25% more call options, than puts
Call options by funds: $11.6M | Put options by funds: $9.24M
6% more funds holding
Funds holding: 148 → 157 (+9)
35% less capital invested
Capital invested by funds: $1.01B → $653M (-$357M)
50% less funds holding in top 10
Funds holding in top 10: 4 → 2 (-2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RG
Redmile Group
San Francisco,
California
|
+$24.5M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$7.27M |
| 3 |
Millennium Management
New York
|
+$5.93M |
| 4 |
State Street
Boston,
Massachusetts
|
+$4.79M |
| 5 |
State of Wisconsin Investment Board
Madison,
Wisconsin
|
+$3.26M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$12.6M |
| 2 |
BBA
Baker Bros. Advisors
New York
|
-$6.95M |
| 3 |
Two Sigma Investments
New York
|
-$5.27M |
| 4 |
GC
Guggenheim Capital
Chicago,
Illinois
|
-$5.03M |
| 5 |
TC
TFS Capital
West Chester,
Pennsylvania
|
-$3.98M |
ARRY Hedge Fund Activity: Q3 2015 in Review
157 of the 3,590 institutional investors tracked by Wall St. Rank reported a position in Array Biopharma Inc (ARRY) for Q3 2015, worth a combined $653M — down 35% from $1.01B a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new ARRY positions and 16 closed out — a net gain of 10 holders — while 57 added to existing stakes and 44 trimmed.
The largest buyer was Redmile Group, adding an estimated $24.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $12.6M.
- 157 institutional investors held Array Biopharma Inc (ARRY) as of Q3 2015, up from 148 in Q2 2015.
- Funds reported $653M of Array Biopharma Inc stock for Q3 2015, down 35% quarter-over-quarter.
- 26 funds opened new Array Biopharma Inc positions in Q3 2015 and 16 closed out, a net change of +10 holders.
- The largest Array Biopharma Inc buyer in Q3 2015 was Redmile Group, an estimated $24.5M added.
- The largest Array Biopharma Inc seller in Q3 2015 was T. Rowe Price Associates, an estimated $12.6M sold.
Based on aggregated 13F filings for Q3 2015.